Inhalable medicines are already widely used to treat conditions such as asthma, epilepsy, allergies and Parkinson’s but delivery options have been limited due to user accessibility, cost, and impact on the environment, 1nhaler said.
The company claims to have developed a way of enabling many different dry powder drugs to be delivered in a low-cost delivery device.
The funding round was led by Archangels with support from Dr Yusuf Hamied, British Business Investments (BBI) and other seed investors.
Lisa McMyn, CEO and founder at 1nhaler, said: “Our DPI has the potential to become the simplest, most convenient single-dose, disposable inhaler on the market, revolutionising the delivery of critical drugs, without the cost and environmental impact of existing devices.
“Securing funding from Archangels is invaluable for the next steps in the 1nhaler’s development. Their life sciences expertise and patient capital approach are exactly what we’re looking for in a funding partner.”
While many inhalers are made from plastic and are expensive to manufacture, 1nhaler’s DPI is cardboard-based with the same dimensions as a credit card.
The platform technology also includes a breathable membrane which can be tailored to deliver individual drugs to patients.
This latest investment will allow 1nhaler to work with other companies to bring new and existing drugs to patients.
Dr Sarah Hardy, director and head of new Investments at Archangels, commented: “Don, Lisa and the team at 1nhaler have developed a truly innovative technology platform with a clear route to market and opportunity to positively disrupt the status quo of single-dose medicine delivery.
“We’re proud to add 1nhaler to our portfolio of Scotland’s leading life sciences and technology businesses and look forward to working with them to increase the availability of life-saving drugs affordably and sustainably.”
